Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer

This study tests a personalized cell therapy called GT307 — made from immune cells extracted from the patient's own tumor (tumor-infiltrating lymphocytes) — for people with advanced colorectal cancer that has progressed despite chemotherapy. **You may be eligible if...** - You are between 18 and 70 years old - You have advanced colorectal cancer that progressed after at least one line of chemotherapy - You are in reasonably good health (ECOG 0 or 1) - You have at least one measurable tumor on imaging - Your expected survival is at least 12 weeks - Your major organs are functioning adequately **You may NOT be eligible if...** - Your tumor pain is uncontrollable - You have active brain metastases - You have serious infections or autoimmune conditions - You are pregnant or breastfeeding - You have received certain prior immunotherapies Talk to your doctor to see if this trial is right for you.